The Relationship of Initial Transferrin Saturation to Cardiovascular Parameters and Outcomes in Patients Initiating Dialysis

Hyang Mo Koo1, Chan Ho Kim1, Fa Mee Doh1, Mi Jung Lee1, Eun Jin Kim1, Jae Hyun Han1, Ji Suk Han1, Hyung Jung Oh1, Jung Tak Park1, Seung Hyeok Han1, Tae-Hyun Yoo1, Shin-Wook Kang1,2*

1 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, 2 Brain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul, Korea

Abstract

Background: The prognostic importance of anemia for cardiovascular (CV) events and mortality has been extensively investigated. However, little is known about the impact of transferrin saturation (TSAT), a marker reflecting the availability of iron for erythropoiesis, on clinical outcome in dialysis patients.

Methods: A total of 879 anemic incident dialysis patients were recruited from the Clinical Research Center for End-Stage Renal Disease in Korea and were divided into 3 groups according to baseline TSAT of ≤20%, 20–40%, and >40%.

Results: There were no differences in hemoglobin levels and the proportion of patients on erythropoiesis-stimulating agents or iron supplements among the 3 groups. During a mean follow-up duration of 19.3 months, 51 (5.8%) patients died. CV composite (11.71 vs. 5.55 events/100 patient-years, P = 0.001) and all-cause mortality rates (5.38 vs. 2.31 events/100 patient-years, P = 0.016) were significantly higher in patients with TSAT ≤20% compared to those with TSAT 20–40% (reference group). Cox regression analysis revealed that patients with TSAT ≤20% had 1.62- and 2.19-fold higher risks for CV composite outcome (P = 0.046) and all-cause mortality (P = 0.030). Moreover, TSAT ≤20% was significantly associated with left ventricular hypertrophy [odds ratio (OR) = 1.46], high-sensitivity C-reactive protein ≥3 mg/dL (OR = 2.09), N-terminal pro B-type natriuretic peptide ≥10000 pg/mL (OR = 2.04), and troponin-T ≥0.1 ng/mL (OR = 2.02), on logistic regression analysis.

Conclusions: Low TSAT was a significant independent risk factor for adverse clinical outcome in incident dialysis patients with anemia, which may be partly attributed to cardiac dysfunction and inflammation.

Introduction

Anemia is prevalent in patients with chronic kidney disease (CKD), and develops during the early stages of the disease and worsens as renal function declines [1,2]. It is well known that anemia is closely linked with fatigue, exercise intolerance, and poor quality of life. In addition, anemia has been demonstrated to be an independent risk factor for left ventricular hypertrophy (LVH), congestive heart failure (CHF), and cardiovascular (CV) mortality [3–5]. In CKD patients, anemia is also associated with the progression of renal dysfunction [6,7].

Anemia in CKD patients is attributed to inadequate production of erythropoietin, iron and/or folate deficiency, secondary hyperparathyroidism, chronic inflammation, and bone marrow suppression due to uremic toxins [9]. Among these factors except for erythropoietin deficiency, iron deficiency is the leading cause of anemia in patients with CKD. Therefore clinicians must determine patients’ iron levels not only at the start of erythropoeis-stimulating agent (ESA) therapy but also monitor iron levels during ESA treatment in this population [9,10]. To evaluate iron status, serum iron concentrations, transferrin saturation (TSAT); the ratio of serum iron to total iron-binding capacity (TIBC), multiplied by 100, and serum ferritin levels are commonly used. While serum iron concentrations and TSAT reflect the amount of iron available for erythropoiesis, serum ferritin levels are the only marker of total body iron stores. Ferritin levels also are greatly influenced by nutritional and/or inflammatory status and do not correlate well with bone marrow findings in patients with various chronic diseases [11]. Considering these findings, TSAT <20% and serum ferritin concentrations <100 ng/mL are regarded as absolute iron deficiency, and TSAT <20% and serum ferritin levels >100 ng/mL as relative iron deficiency [9,11].

Iron is an essential nutrient. It plays critical roles in binding and transporting oxygen, oxidative metabolism by serving as a component of the mitochondrial respiratory chain proteins, and
the synthesis of DNA and protein [12]. Therefore, iron deficiency may result in numerous pathologies, especially in cells with high energy demands, such as cardiomyocytes [13,14]. In addition to its association with poor cognitive function, reduced exercise performance, and decreased quality of life, previous studies have found that absolute or relative iron deficiency, regardless of the presence of anemia, is an independent predictor of adverse clinical outcomes, including a progression of CHF and mortality, in patients with CHF [15–18]. These findings suggest that lack of circulating available iron has a direct deleterious effect on the heart.

Since CV disease is the most common cause of morbidity and mortality in patients with end-stage renal disease (ESRD), it follows that iron deficiency may have a negative impact on the clinical outcome of ESRD patients. However, to date, this effect has never been evaluated in this population. In the present study, therefore, we investigated whether low TSAT was a significant predictor of CV mortality/composite outcome and all-cause mortality in Korean incident dialysis patients from the Clinical Research Center (CRC) for ESRD. The relationships of TSAT with echocardiographic parameters and cardiac biomarkers were also defined in these patients.

**Patients and Methods**

**Ethics statement**

This study was carried out in accordance with the Declaration of Helsinki and study protocol was approved by the Institutional Review Board of each participating hospital’s Clinical Trial Center (CTC); Kyungpook National University Hospital CTC, Youngnam University Medical Center CTC, Dong-A University Medical Center CTC, Busan National University Hospital CTC, Inje University Pusan Paik Hospital CTC, Ulsan University Hospital CTC, Seoul National University Hospital CTC, Seoul National University Bundang Hospital CTC, Seoul National University Boramae Hospital CTC, Gachon University Gil Medical Center CTC, Yonsei University Health System CTC, National Health Insurance Corporation Ilsan Hospital CTC, Ehwa Womans University Mokdong Hospital CTC, Kwandong University College of Medicine Myongji Hospital CTC, Kangnam Severance Hospital CTC, The Catholic University of Korea Seoul St. Mary’s Hospital CTC, The Catholic University of Korea Yonsei St. Mary’s Hospital CTC, The Catholic University of Korea Bucheon St. Mary’s Hospital CTC, The Catholic University of Korea St. Vincent’s Hospital CTC, The Catholic University of Korea Uijeongbu St. Mary’s Hospital CTC, Chung-Ang University Health System CTC, Chonnam National University Hospital CTC, Chungnam National University Hospital CTC, Chungbuk National University Hospital CTC, Chonbuk National University Hospital CTC, and Cheju Halla General Hospital CTC. All patients provided their written informed consent before entering the study.

**Patients**

Initial recruitment for this prospective observational multicenter study included all ESRD patients who started dialysis between August 1, 2008 and December 31, 2012 at 27 centers of the CRC for ESRD in Korea. Among these patients, we excluded those who were younger than 18 years old, had a history of kidney transplantation prior to dialysis therapy, had an underlying active malignancy or acute infection, or died within 3 months of the initiation of dialysis. Patients who were not anemic; anemia was defined as a Hb <13 g/dL in men and <12 g/dL in women according to World Health Organization (WHO) criteria [19], had a recent bleeding episode, or had insufficient baseline data were also excluded from the study. Ultimately, a total of 879 incident dialysis patients were included in the final analysis.

**Data Collection**

Demographic and clinical data were recorded at the time of study entry, including age, gender, body mass index (BMI) calculated as weight/height², primary renal disease, comorbidities, and medications. Coronary arterial disease (CAD) was defined as a history of angioplasty, coronary artery bypass grafts, myocardial infarction, or angina, while peripheral arterial disease (PAD) was defined as a history of claudication, ischemic limb loss and/or ulceration, or peripheral revascularization procedure. At the time of study entry and every 3 months thereafter, laboratory data were measured from fasting blood samples, which were drawn prior to the start of hemodialysis (HD) on the day of a midweek session in HD patients and at 2-hours after the first peritoneal dialysis (PD) exchange with 1.5% dextrose dialysate in PD patients. The estimated glomerular filtration rate (eGFR) was calculated using the four-variable Modification of Diet in Renal Disease study (MDRD) and Chronic Kidney Disease Epidemiology Collaboration study (CKD-EPI) equations [20]. In addition, a 24-hour urine collection was performed to determine residual urine volume, and 24-hour urinary protein, urea, and creatinine excretion. Nutritional status was also evaluated by the subjective global assessment (SGA) score [21]. The quality of life was assessed using a Korean version of Kidney Disease Quality of Life Short Form (KDQOL-SF, version 1.3) [22].

Echocardiography was performed on a non-dialysis day in HD patients and in the morning with an empty abdomen in PD patients, close to the time of discharge, based on the imaging protocol recommended by the American Society of Echocardiography. Left atrial dimension (LAD) was assessed at the end of the ventricular systole at the level of the aortic valve, according to the leading-edge-to-leading-edge convention. Left ventricular (LV) mass was calculated using the method described by Devereux et al. [23], and the LV mass index (LVMI) was calculated by dividing LV mass by body surface area. LV hypertrophy (LVH) was defined as a LVMI >131 g/m² for men and >100 g/m² for women [24]. LV systolic function was estimated by the LV ejection fraction (LVEF) using a modified biplane Simpson’s method from the apical two-chamber and four-chamber views. Inter-ventricular septal thickness (IST), left ventricular posterior wall thickness (LVPWT), and left ventricular dimensions (LVEDD, LVEDS) were also measured at the end of both the diastolic and systolic phases. Multiple reproducibility, inter-reader reliability, intra-reader reliability, and reader drift analyses were performed at a core echocardiography laboratory (Kyungpook National University, Daegu, Korea) on a random sample of 3% of the entire cohort each year. The intra-class correlation coefficients for the echocardiographic measures were 0.773 for LAD, 0.745 for LVMI, and 0.842 for LVEF.

**Outcome measures**

For the current study, all mortality and hospitalization event records were retrieved from the CRC for ESRD database and carefully reviewed. The primary endpoints were CV mortality and CV composite outcome (death and hospitalization), and the secondary endpoint was all-cause mortality. CV event was considered death or hospitalization from myocardial infarction/ischemia, congestive heart failure, pulmonary edema, or cerebrovascular disorder.
Statistical analysis
Statistical analysis was performed using SPSS for Windows, version 18.0 (SPSS Inc., Chicago, IL, USA). Data are expressed as mean ± standard deviation or median (interquartile range) for continuous variables, and as a number (percentage) for categorical variables. Normality of distribution was assessed by the Shapiro-Wilk test. Patients were categorized into 3 groups according to TSAT concentrations; ≤20%, 20–40%, and >40%. Patient demographics, clinical characteristics, and laboratory findings were compared among the three groups using ANOVA or Kruskal-Wallis test for continuous variables and the chi-square test for categorical variables. Cumulative survival curves for CV mortality, CV composite outcome, and all-cause mortality were created by the Kaplan-Meier method, and between-group survival was compared by a log-rank test. The independent prognostic power of TSAT for clinical outcomes was ascertained by multivariate Cox proportional hazards regression analysis, which included only the variables of a P-value <0.10 on the univariate analysis. Binary logistic regression analysis was conducted to determine the independent predictive value of TSAT for echocardiographic parameters (LVEF <60%, LVH, LVESD ≥55 mm, LVEDD ≥55 mm, and LAD ≥40 mm) and inflammatory and cardiac biomarkers [high-sensitivity C-reactive protein (hs-CRP) ≥3 mg/dL, N-terminal pro B-type natriuretic peptide (NT-proBNP) ≥10000 pg/mL, and cardiac troponin-T (cTnT) ≥0.1 ng/mL]. A P-value of less than 0.05 was considered statistically significant.

Results
Baseline characteristics
The baseline demographics and clinical characteristics are shown in Table 1. The mean age was 56.4±14.5 years, and 59.6% of patients were male. The most common cause of ESRD was diabetes (DM, 52.7%), followed by hypertension (16.5%). A total of 645 patients (73.4%) were treated with HD and 294 patients (26.6%) with PD. The mean values of hemoglobin (Hb) and TSAT were 8.6±1.4 g/dL and 28.4±16.0%, respectively, and the median levels of ferritin were 201.3 (103.5–363.4) ng/mL.

When patients were divided into three groups according to baseline TSAT concentrations, age, sex, the proportion of patients on HD, the presence of DM and CV diseases, and KDQOL-SF scores were comparable among the three groups. There were also no differences in the proportions of patients on renin-angiotensin system (RAS) blockers, ESA, and supplementary iron. However, beta-blockers were more frequently prescribed in the lowest TSAT group compared to the highest TSAT group (P = 0.019) (Table 1). Even though only one third of patients (n=319, 36.3%) were on iron therapy at 3-month, the median levels of ferritin were 201.3 (103.5–363.4) ng/mL.

Within the laboratory and echocardiographic findings, blood urea nitrogen and creatinine levels were significantly lower in the lowest TSAT group compared to the highest TSAT group (P < 0.001), whereas serum calcium, bicarbonate, and triglyceride concentrations were significantly higher (P < 0.05). There were also significant gradual increases in serum iron and ferritin concentrations and a significant gradual decrease in TIBC levels across the TSAT groups (P < 0.001). However, eGFR and Hb concentrations were not significantly different among the three groups. Meanwhile, hs-CRP and NT-proBNP levels were significantly higher in the lowest TSAT group compared to the other two groups (P < 0.001 and P = 0.011, respectively). Echocardiographic parameters were comparable among the three groups (Table 2).

CV mortality, CV composite outcome, and all-cause mortality according to TSAT concentrations
During a mean follow-up duration of 19.3±11.8 months, 51 patients (5.8%) died. Among them, 29 patients (3.5%) died from CV causes and 12 (1.4%) from infection.

Compared to the reference group (TSAT 20–40%), CV composite and all-cause mortality rates were significantly higher in patients with TSAT ≤20% (CV composite: 11.71 vs. 5.55 events per 100 patient-yr, P = 0.001; all-cause mortality: 5.38 vs. 2.31 events per 100 patient-yr, P = 0.016). In contrast, there was no significant difference in CV mortality rates among the three groups (Table 3). Kaplan-Meier analysis also showed that the CV composite and all-cause mortality rates were significantly higher in patients with TSAT ≤20% compared to the other two groups (P = 0.009 and P = 0.046, respectively) (Figure 1). However, there was no significant difference in the CV composite and all-cause mortality rates between the reference and TSAT >40% groups.

Multivariate Cox-proportional hazard regression analysis revealed that patients in the lowest TSAT group had 1.62- and 2.19-fold higher risks for CV composite outcome and all-cause mortality, respectively, even after adjusting for demographic characteristics, laboratory findings, and echocardiographic parameters (P = 0.046 and P = 0.030, respectively) (Table 4).

In another analysis, we simply dichotomized patients into ‘low’ and ‘normal to high’ TSAT groups based on TSAT concentrations of 20%, and compared the clinical outcomes between the two groups. The ‘low’ TSAT group had significantly higher rates of CV composite (11.71 vs. 6.15 events per 100 patient-yr, P < 0.001) and all-cause mortality (5.38 vs. 2.74 events per 100 patient-yr, P = 0.008) than patients with TSAT >20%, and the hazard ratios (HRs) were 1.53 and 2.04, respectively, on the multivariate Cox regression analysis (Table S1 and S2, and Figure S1).

Relationships between TSAT and echocardiographic parameters
In binary logistic regression analysis for echocardiographic parameters, TSAT ≤20% was demonstrated to be significantly associated with LVH [odds ratio (OR) = 1.46, P = 0.048]. The ORs of TSAT ≤20% for LVEF <60%, LVESD ≥55 mm, LVEDD ≥55 mm, and LAD ≥40 mm were also increased, but did not reach statistical significances (Table 5).

Based on these results, we performed an additional multivariate linear regression analysis for LVMI. Along with diastolic blood pressure, underlying CV disease, SGA score, smoking status, serum Hb and albumin concentrations, and usage of RAS blockers, calcium-based phosphate binders, and iron agents, TSAT ≤20% was a significant independent determinant of LVMI (R = 7.151, P = 0.044) (Table S3).

Relationships between TSAT and serum inflammatory and cardiac biomarkers
In binary logistic regression analysis revealed that there were significant independent associations of TSAT ≤20% with hs-CRP ≥3 mg/dL (OR = 2.09, P = 0.003), NT-proBNP ≥10,000 pg/mL (OR = 2.04, P = 0.011), and cTnT ≥0.1 ng/mL (OR = 2.02, P = 0.02) (Table 6).

In an additional multivariate linear regression analysis, TSAT ≤20% was found to be a significant determinant of natural log values (Ln) of hs-CRP levels (R = 0.304, P < 0.001), but not of Ln
| Variables                                      | Total | TSAT ≤20% | TSAT 20–40% | TSAT >40% | P    |
|-----------------------------------------------|-------|-----------|-------------|-----------|------|
| N                                             | 879   | 282       | 431         | 166       |      |
| Age (years)                                   | 56.4±14.5 | 57.1±14.0 | 56.4±14.2   | 55.3±16.2 | 0.414|
| Sex (Male)                                    | 524 (59.6) | 162 (57.4) | 258(59.9)   | 104 (62.7) | 0.550|
| BMI (kg/m²)                                   | 23.2±3.7 | 23.3±3.7   | 23.4±3.8    | 22.6±3.3  | 0.097|
| Systolic BP (mmHg)                            | 142.4±24.7 | 142.2±24.7 | 142.7±25.4  | 141.7±22.9 | 0.898|
| Diastolic BP (mmHg)                           | 77.6±15.2 | 76.9±15.0  | 77.8±15.3   | 78.1±15.1 | 0.666|
| Heart rate (beat per minute)                  | 76.7±13.6 | 76.9±13.0  | 76.8±13.1   | 76.2±15.7 | 0.845|
| Dialysis modality (HD)                        | 645 (73.4) | 212 (75.2) | 310 (71.9)  | 123 (74.1) | 0.614|
| Follow-up duration (months)                   | 19.3±11.8 | 19.8±11.6  | 19.3±11.7   | 18.6±12.3 | 0.562|
| Smoking status                                |       |           |             |           | 0.878|
| Current smoker                                | 103 (11.7) | 31 (11.0)  | 51 (11.8)   | 21 (12.7) |      |
| Ex-smoker                                     | 291 (33.1) | 92 (32.6)  | 143 (33.2)  | 56 (33.7) |      |
| Non-smoker                                    | 467 (53.1) | 155 (55.0) | 225 (52.2)  | 87 (52.4) |      |
| Unknown                                       | 18 (2.0)  | 4 (1.4)    | 12 (2.8)    | 2 (1.2)   |      |
| Primary cause of end-stage renal disease      |       |           |             |           | 0.151|
| Diabetes                                      | 463 (52.7) | 162 (57.4)| 228 (52.9)  | 73 (44.0) |      |
| HTN/Large vessel disease                      | 145 (16.5) | 43 (15.2)  | 75 (17.4)   | 27 (16.3) |      |
| Glomerulonephritis                            | 147 (16.7) | 38 (13.5)  | 67 (15.5)   | 42 (25.3) |      |
| Interstitial nephritis                        | 9 (1.0)   | 3 (1.1)    | 5 (1.2)     | 1 (0.6)   |      |
| Hereditary/Congenital disease                 | 15 (1.7)  | 7 (2.5)    | 6 (1.4)     | 2 (1.2)   |      |
| Others                                        | 43 (4.9)  | 11 (3.9)   | 24 (5.6)    | 8 (4.8)   |      |
| Unknown                                       | 57 (6.5)  | 18 (6.4)   | 26 (6.0)    | 13 (7.8)  |      |
| Comorbid disease                              |       |           |             |           |      |
| Chronic lung disease                          | 72 (8.2)  | 20 (7.1)   | 32 (7.4)    | 20 (12.0) | 0.130|
| CAD                                           | 127 (14.4) | 48 (17.0)  | 57 (13.2)   | 22 (13.3) | 0.329|
| PAD                                           | 65 (7.4)  | 22 (7.8)   | 36 (8.4)    | 7 (4.2)   | 0.213|
| CVA                                           | 92 (10.5) | 29 (10.3)  | 47 (10.9)   | 16 (9.6)  | 0.896|
| CHF                                           | 127 (14.4) | 42 (14.9)  | 65 (15.1)   | 20 (12.0) | 0.619|
| Arrhythmia                                    | 25 (2.8)  | 6 (2.1)    | 17 (3.9)    | 2 (1.2)   | 0.153|
| Diabetes                                      | 486 (55.3) | 167 (59.2)| 239 (55.5)  | 80 (48.2) | 0.076|
| Connective tissue disease                     | 85 (9.7)  | 25 (8.9)   | 43 (10.0)   | 17 (10.2) | 0.853|
| Liver disease                                 | 81 (9.2)  | 17 (6.0)   | 39 (9.0)    | 25 (15.1) | 0.006|
| CVD*                                          | 298 (33.9) | 102 (36.2)| 141 (32.7)  | 55 (33.1) | 0.618|
| Cardiac disease†                               | 224 (25.5) | 78 (27.7)  | 107 (24.8)  | 39 (23.5) | 0.563|
| Modified CCI                                  | 5.1±2.6   | 5.1±2.5    | 5.1±2.6     | 4.9±2.6   | 0.665|
| SGA >1                                        | 278 (31.6) | 84 (29.8)  | 144 (33.4)  | 50 (30.1) | 0.535|
| KDQOL-SF score                                | 60.1±14.9 | 60.1±14.8  | 60.5±15.2   | 59.0±14.3 | 0.696|
| Medications                                   |       |           |             |           |      |
| RAS blockers                                  | 528 (60.1) | 167 (59.2)| 259 (60.1)  | 102 (61.4) | 0.898|
| Diuretics                                     | 461 (52.4) | 150 (53.2)| 225 (52.2)  | 86 (51.8) | 0.951|
| Beta blocker                                  | 477 (54.3) | 170 (60.3)| 229 (53.1)  | 78 (47.0) | 0.019|
| CCB                                           | 549 (62.5) | 183 (64.9)| 263 (61.0)  | 103 (62.0) | 0.576|
| Nitrate                                       | 34 (3.9)   | 10 (3.5)   | 13 (3.0)    | 11 (6.6)  | 0.116|
| Aspirin                                       | 214 (24.3) | 81 (28.7)  | 98 (22.7)   | 35 (21.1) | 0.106|
| Clopidogrel                                   | 73 (8.3)   | 31 (11.0)  | 30 (7.0)    | 12 (7.2)  | 0.139|
| Vitamin D                                     | 124 (14.1) | 39 (13.8)  | 70 (16.2)   | 25 (15.1) | 0.680|
| Ca based P-binders                            | 472 (53.7) | 164 (58.2)| 224 (52.0)  | 84 (50.6) | 0.182|
| ESA                                           | 282 (32.1) | 83 (29.4)  | 148 (34.3)  | 51 (30.7) | 0.358|
| Iron agent                                    | 319 (36.3) | 95 (33.7)  | 160 (37.1)  | 64 (38.6) | 0.516|
### Table 2. Laboratory and echocardiographic findings of the patients.

| Variables                   | Total | TSAT ≤20% | TSAT 20–40% | TSAT >40% | P       |
|-----------------------------|-------|-----------|-------------|-----------|---------|
| **Baseline laboratory data** |       |           |             |           |         |
| WBC (×10⁹/L)               | 7239.1±2936.6 | 7637.2±3080.2 | 7055.1±2793.8 | 7039.6±2997.5 | 0.022   |
| Hemoglobin (g/dL)           | 8.5±1.43 | 8.54±1.34 | 8.47±1.41 | 8.44±1.61 | 0.604   |
| ALP (IU/L)                  | 78.0 (59.0–109.0) | 80.0 (60.0–109.0) | 75.0 (57.0–105.0) | 80.5 (59.0–115.3) | 0.065   |
| Ca (mg/dL)                  | 8.22±1.08 | 8.32±0.96 | 8.22±1.05 | 8.06±1.10 | 0.048   |
| P (mg/dL)                   | 5.61±1.38 | 5.59±1.08 | 5.60±1.36 | 5.81±1.81 | 0.106   |
| Ca x P product              | 45.4±15.1 | 45.4±13.7 | 45.3±14.9 | 46.1±17.7 | 0.239   |
| Uric acid (mg/dL)           | 8.36±2.13 | 8.25±2.06 | 8.40±2.07 | 8.50±2.35 | 0.260   |
| Glucose (mg/dL)             | 140.9±37.4 | 141.6±40.7 | 141.9±39.5 | 137.0±25.1 | 0.747   |
| HbA1c (%)                   | 6.12±0.81 | 6.12±0.90 | 6.16±0.75 | 6.02±0.81 | 0.570   |
| Protein (g/dL)              | 6.05±0.80 | 6.08±0.76 | 6.03±0.82 | 6.06±0.82 | 0.702   |
| Albumin (g/dL)              | 3.32±0.59 | 3.29±0.59 | 3.33±0.57 | 3.35±0.61 | 0.522   |
| BUN (mg/dL)                 | 82.7±26.8 | 76.6±22.7 | 82.3±25.7 | 94.4±33.4 | <0.001  |
| Creatinine (mg/dL)          | 8.52±3.52 | 7.97±2.58 | 8.42±3.32 | 9.73±4.98 | <0.001  |
| GFR-MDRD (mL/min/1.73m2)    | 7.17±3.12 | 7.40±3.42 | 7.18±3.14 | 6.51±2.54 | 0.080   |
| GFR-EPI (mL/min/1.73m2)     | 7.29±2.94 | 7.47±2.76 | 7.39±3.16 | 6.72±2.60 | 0.111   |
| Sodium (mEq/L)              | 137.2±4.9 | 137.0±4.6 | 137.3±5.0 | 137.4±5.0 | 0.763   |
| Potassium (mEq/L)           | 4.67±0.95 | 4.61±0.95 | 4.66±0.93 | 4.79±1.01 | 0.115   |
| Total cholesterol (mg/dL)   | 155.2±46.3 | 153.9±44.8 | 156.7±46.9 | 151.5±47.3 | 0.219   |
| Triglyceride (mg/dL)        | 127.1±54.8 | 127.3±64.9 | 129.2±51.0 | 116.7±43.6 | 0.035   |
| LDL-cholesterol (mg/dL)     | 89.3±32.0 | 87.8±29.3 | 92.6±34.7 | 83.6±28.6 | 0.044   |
| HDL-cholesterol (mg/dL)     | 38.6±12.5 | 38.4±11.9 | 38.3±12.2 | 39.9±14.2 | 0.380   |
| hs-CRP (mg/dL)              | 0.32 (0.08–1.46) | 0.71 (0.15–2.09) | 0.24 (0.06–0.99) | 0.25 (0.07–1.20) | <0.001 |
| Troponin-T (mg/mL)          | 0.056 (0.025–0.110) | 0.057 (0.027–0.125) | 0.059 (0.025–0.106) | 0.064 (0.021–0.096) | 0.409 |
| NT-proBNP (pg/mL)           | 650.54 (1576.7–25840.0) | 1101.02 (1998.0–30000.0) | 5969.5 (1364.0–21882.8) | 4903.0 (1269.0–25151.5) | 0.011 |
| **24-hr urine study**       |       |           |             |           |         |
| Urea (mg/dL)                | 220.0 (142.0–327.4) | 190.1 (136.8–293.5) | 238.8 (152.5–347.3) | 266.7 (127.8–325.1) | 0.018   |
| Creatinine (mg/dL)          | 54.1 (38.0–86.6) | 51.5 (36.4–76.0) | 55.9 (38.4–91.3) | 56.2 (36.6–84.1) | 0.119   |
| Protein (mg/day)            | 1180.5 (418.1–2794.5) | 1153.0 (426.2–3150.5) | 1305.6 (393.0–2951.7) | 1053.0 (383.0–2604.0) | 0.723   |
| **Echocardiographic parameters** |       |           |             |           |         |
| LVPWT (cm)                  | 1.20±0.29 | 1.21±0.29 | 1.19±0.29 | 1.20±0.27 | 0.737   |
| LVMi (gm2)                  | 58.2±11.3 | 57.3±12.3 | 58.3±11.1 | 59.3±10.3 | 0.206   |

Abbreviations: WBC, white blood cell; ALP, alkaline phosphatase; Ca, calcium; P, phosphorus; HbA1C, hemoglobin A1C; BUN, blood urea nitrogen; GFR, glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; EPI, Chronic Kidney Disease Epidemiology Collaboration Equation; PTH, parathyroid hormone; TIBC, total iron binding capacity; TSAT, transferrin saturation; LDL, low density lipoprotein; HDL, high density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; NT-proBNP, N-terminal pro B-type natriuretic peptide; LVPWT, left ventricular posterior wall thickness; IST, inter-ventricularseptalthickness; LVEDD, left ventricular end-diastolic dimension; LAD, left atrial dimension; LVMi, left ventricular mass index; LVEF, left ventricular ejection fraction.

doi:10.1371/journal.pone.0087231.t002
Discussion

TSAT is one of the available markers reflecting the adequacy of iron for erythropoiesis and is closely correlated with Hb levels [9,11]. Even though a number of studies have shown that anemia is an independent risk factor for CV events and mortality in ESRD patients, as well as in the general population [3,4,7,25], the impact of TSAT on clinical outcome has never been explored in dialysis patients. In the current study on incident dialysis patients with anemia, we demonstrate for the first time that the lowest TSAT group has significantly higher risk for CV composite outcome and all-cause mortality, irrespective of Hb concentrations. In addition, TSAT # 20% was significantly associated with LVMI and hs-CRP levels. These findings suggest that the adverse clinical outcomes in patients with ‘low’ TSAT are partly attributed to LVH and inflammation.

Iron deficiency is the most frequent cause of anemia in the general population. In ESRD patients, a decrease in the production of erythropoietin is the main factor contributing to anemia, but iron deficiency anemia (IDA) is also prevalent [8]. Even though anemia has been demonstrated to be an independent risk factor for renal function deterioration and CV morbidity/mortality in patients with CKD [4,7,25], the results of some previous studies on the impact of anemia correction on the clinical outcome of CKD/ESRD patients have not been promising, except for some improvement in quality of life [26–28]. Similarly, anemia is common in patients with CHF, most of which are attributed to ‘anemia of chronic disease’ or iron deficiency [5,29,30]. Numerous previous studies demonstrated that anemia was associated with impaired functional capacity and poor quality of life in CHF patients, which were ameliorated by elimination of the anemia [31,32]. However, a body of evidence indicating that anemia correction has a beneficial effect on CV mortality in these patients is lacking. Based on these findings, it is still debatable whether adverse clinical outcomes in anemic patients are attributed to anemia per se or other factors contributing to anemia.

Iron is essential for normal cell physiology. In addition to its critical role in erythropoiesis, iron is involved in the process of oxygen transport and storage, oxidative metabolism including ATP (adenosine triphosphate) production at the mitochondrial electron transport chain in the form of cytochrome (a, b, c) and iron-sulfur-containing dehydrogenases, and the synthesis and/or degradation of RNA and DNA. Therefore, iron deficiency can lead to not only anemia but also various cellular dysfunctions, especially in high energy-requiring cells such as cardiomyocytes and renal cells. In the clinical field, reduced oxidative capacity caused by cytochrome dysfunction can manifest as fatigue, impaired prolonged exercise, malnutrition, and cardiac dysfunction [12,33,34]. A previous study by Dong et al. [13] showed that heart weight and size were significantly increased, and the left

| TSAT ≤20% | 20% < TSAT ≤40% | TSAT >40% |
|-----------|----------------|-----------|
| N (%)     | Rates (per 100 patient-yr) | N (%) | Rates (per 100 patient-yr) | P |
| CV mortality | 12 (4.3%) | 2.58 | 10 (2.3%) | 1.44 | 7 (4.2%) | 2.73 | 0.281 |
| CV composite | 51 (18.1%) | 11.71 | 37 (8.6%) | 5.55 | 19 (11.4%) | 7.78 | 0.001 |
| All-cause mortality | 25 (8.9%) | 5.38 | 16 (3.7%) | 2.31 | 10 (6.0%) | 3.90 | 0.016 |

*Composite: composite of death and hospitalization.
Abbreviations: TSAT, transferrin saturation; CV, cardiovascular.

Table 3. Comparisons of clinical outcomes according to the TSAT concentrations.

The Impact of TSAT on Clinical Outcome
ventricular dimension and chamber volume were significantly enhanced, in rats fed an iron-deficient diet for 12 weeks. Mitochondrial swelling and abnormal sarcomere structure were also observed in ventricular tissues of the iron-deficient rats. These findings inferred that iron deficiency per se might induce cardiac dysfunction and morphological aberration. Moreover, another recent study demonstrated that patients with advanced CHF had significantly lower systolic CHF. Patients with iron deficiency had significantly lower survival rates, either when death and heart transplantation or death alone were considered events in both univariate and multivariate Cox regression models, whereas anemia was a significant predictor of adverse clinical outcome only in univariate analysis. Based on these findings, they suggested that iron deficiency had a direct deleterious effect on cardiomyocytes.

The results of the present study also showed that clinical outcome and all-cause mortality. Taken together, we surmise that the association between low TSAT and adverse clinical outcome in incident dialysis patients is a consequence of iron deficiency rather than anemia in the heart, which may be partly attributed to mitochondrial cytochrome dysfunction.

| Table 4. Hazard ratios and 95% confidence intervals for primary and secondary endpoints according to baseline TSAT concentrations (Cox-proportional hazard regression analysis). |
|------------------|------------------|------------------|
|                  | CV mortality     | CV composite     | All-cause mortality |
|                  | HR 95% CI P      | HR 95% CI P      | HR 95% CI P         |
| Unadjusted       |                  |                  |                    |
| TSAT ≤20%        | 1.798 0.777–4.161 0.171 | 1.918 1.256–2.929 0.003 | 2.117 1.130–3.965 0.019 |
| 20% < TSAT ≤40%  | 1 - -            | 1 - -            | 1 - -              |
| TSAT >40%        | 1.881 0.716–4.941 0.200 | 1.420 0.817–2.469 0.214 | 1.714 0.778–3.777 0.182 |
| Adjusted for demographics |                  |                  |                    |
| TSAT ≤20%        | 1.651 0.710–3.841 0.245 | 1.729 1.123–2.661 0.013 | 2.278 1.190–4.363 0.013 |
| 20% < TSAT ≤40%  | 1 - -            | 1 - -            | 1 - -              |
| TSAT >40%        | 1.785 0.675–4.724 0.243 | 1.499 0.859–2.616 0.154 | 1.749 0.760–4.026 0.189 |
| Adjusted for demographics and medications |                  |                  |                    |
| TSAT ≤20%        | 1.635 0.701–3.813 0.255 | 1.645 1.066–2.539 0.025 | 2.002 1.041–3.852 0.038 |
| 20% < TSAT ≤40%  | 1 - -            | 1 - -            | 1 - -              |
| TSAT >40%        | 1.797 0.679–4.755 0.238 | 1.488 0.851–2.603 0.163 | 1.814 0.790–4.165 0.160 |
| Adjusted for demographics, medications, and laboratory parameters |                  |                  |                    |
| TSAT ≤20%        | 1.448 0.608–3.445 0.403 | 1.668 1.049–2.652 0.030 | 2.128 1.057–4.283 0.034 |
| 20% < TSAT ≤40%  | 1 - -            | 1 - -            | 1 - -              |
| TSAT >40%        | 1.587 0.583–3.415 0.366 | 1.323 0.751–2.331 0.332 | 1.432 0.613–3.343 0.407 |
| Adjusted for demographics, medications, laboratory parameters, and echocardiographic findings |                  |                  |                    |
| TSAT ≤20%        | 1.383 0.555–3.448 0.486 | 1.616 1.008–2.607 0.046 | 2.193 1.081–4.450 0.030 |
| 20% < TSAT ≤40%  | 1 - -            | 1 - -            | 1 - -              |
| TSAT >40%        | 1.687 0.580–4.908 0.337 | 1.212 0.673–2.185 0.522 | 1.292 0.533–3.129 0.571 |

*Composite: composite of death and hospitalization.
*CV mortality was sequentially adjusted for demographics (age, diabetes, underlying cardiovascular disease, and subjective global assessment score), medications (aspirin), laboratory parameters (albumin, glucose, alkaline phosphatase, and log transformed high-sensitivity C-reactive protein), and echocardiographic findings (left ventricular mass index and left ventricular ejection fraction).
*CV composite was sequentially adjusted for demographics (age, systolic blood pressure, diabetes, and underlying cardiovascular disease), medications (aspirin, clopidogrel, vitamin D, and erythropoiesis-stimulating agents), laboratory parameters (calcium, glucose, potassium, log transformed ferritin, and log transformed high-sensitivity C-reactive protein), and echocardiographic findings (left ventricular mass index and left ventricular ejection fraction).
*All-cause mortality was sequentially adjusted for demographics (body mass index, Charlson Comorbidity Index, and subjective global assessment score), medications (aspirin, clopidogrel, and vitamin D), laboratory parameters (alkaline phosphatase, calcium, glucose, log transformed ferritin, and log transformed high-sensitivity C-reactive protein), and echocardiographic findings (left ventricular mass index and left ventricular ejection fraction).

Abbreviations: TSAT, transferrin saturation; CV, cardiovascular; HR, hazard ratio; CI, confidence interval.
status in these patients, along with an improvement in LVEF, New York Heart Association (NYHA) functional class, exercise capacity, and quality of life. However, they found that Hb levels were also significantly increased in the treatment group compared to the placebo group. Recently, two prospective randomized controlled trials showed that the correction of iron deficiency with intravenous iron conferred symptomatic benefits in patients with CHF [36,57]. Compared to the control group, patient global assessment, exercise capacity, and NYHA functional class were significantly improved in the iron-treated group regardless of the presence of anemia, suggesting that iron deficiency per se was detrimental to the heart. Considering the results of our study, further studies on the use of intravenous iron in incident ESRD patients with ‘low’ TSAT will be necessary to clarify whether iron therapy can improve the clinical outcome of these patients, as in CHF patients.

Meanwhile, an excess of iron can be toxic because it has the ability to accept and donate electrons by exchanging between ferrous and ferric forms. During this exchange, active free iron undergoes “Fenton and Haber-Weiss reaction”, causing oxidative stress and organic biomolecule oxidation by releasing hydroxyl radicals and other reactive oxygen species (ROS) [38,39]. Furthermore, in the vasculature, ROS produced at the endothelium by excessive iron is known to promote the thrombotic complications [33]. Even though ferritin concentration is usually considered a marker of iron store and has been demonstrated to be an independent predictor of clinical outcomes in not only the general population but also specific patients groups, several previous studies have found that TSAT, an indicator of a predisposition for iron overload, is also a significant prognostic factor in the general population. A cohort study using data from the First Health and Nutrition Examination Survey I (NHANES I) merged with the NHANES I Epidemiologic Follow Up Study showed that all-cause mortality was significantly increased in patients with a serum TSAT of more than 55% compared with those with saturations below this cutoff [HR = 1.60, 95% confidence interval [CI] = 1.17–2.21], on a Cox proportional hazard regression analysis [40]. In addition, Ellervik et al. [41] examined mortality according to baseline TSAT in two Danish population-based follow-up studies and demonstrated that the cumulative survival was significantly reduced in individuals with TSAT ≥50% vs. <50% [P<0.0001]. In that study, there was a

| Table 5. Odds ratios and 95% confidence intervals for echocardiographic parameters according to baseline TSAT concentrations (Logistic regression analysis). |
|-----------------------------------------------|
|                                | Unadjusted |            |            | Adjusted              |            |            |
|                                | OR  | 95% CI   | P    | OR  | 95% CI   | P    |
| Left ventricular ejection fraction <60% |     |          |      |     |          |      |
| TSAT ≤20%                       | 1.435 | 1.068–1.926 | 0.016 | 1.313 | 0.910–1.895 | 0.146 |
| 20% < TSAT ≤40%                 | 1   | -         | -    | 1   | -         | -    |
| TSAT >40%                       | 0.969 | 0.689–1.363 | 0.857 | 0.715 | 0.466–1.096 | 0.124 |
| Left ventricular hypertrophy    |     |          |      |     |          |      |
| TSAT ≤20%                       | 1.482 | 1.065–2.062 | 0.020 | 1.455 | 1.003–2.110 | 0.048 |
| 20% < TSAT ≤40%                 | 1   | -         | -    | 1   | -         | -    |
| TSAT >40%                       | 0.838 | 0.574–1.224 | 0.361 | 0.931 | 0.604–1.435 | 0.747 |
| Left ventricular end-diastolic dimension ≥55 mm |     |          |      |     |          |      |
| TSAT ≤20%                       | 1.363 | 0.981–1.892 | 0.065 | 1.258 | 0.849–1.862 | 0.252 |
| 20% < TSAT ≤40%                 | 1   | -         | -    | 1   | -         | -    |
| TSAT >40%                       | 0.941 | 0.624–1.418 | 0.770 | 0.765 | 0.474–1.235 | 0.274 |
| Left ventricular end-systolic dimension ≥35 mm |     |          |      |     |          |      |
| TSAT ≤20%                       | 1.346 | 0.995–1.821 | 0.054 | 1.341 | 0.935–1.924 | 0.111 |
| 20% < TSAT ≤40%                 | 1   | -         | -    | 1   | -         | -    |
| TSAT >40%                       | 0.888 | 0.617–1.277 | 0.522 | 0.687 | 0.449–1.052 | 0.084 |
| Left atrial dimension ≥40 mm    |     |          |      |     |          |      |
| TSAT ≤20%                       | 1.456 | 1.051–2.015 | 0.024 | 1.145 | 0.777–1.689 | 0.494 |
| 20% < TSAT ≤40%                 | 1   | -         | -    | 1   | -         | -    |
| TSAT >40%                       | 0.835 | 0.578–1.205 | 0.335 | 0.725 | 0.468–1.124 | 0.150 |

*Left ventricular ejection fraction was adjusted for sex, body mass index, heart rate, underlying diabetes and cardiovascular disease, hemoglobin, serum glucose, albumin, and creatinine levels, log transformed high-sensitivity C-reactive protein, and usage of diuretics, beta blockers, and vitamin D.

*Left ventricular hypertrophy was adjusted for sex, diastolic blood pressure, underlying cardiac disease, subjective global assessment score, hemoglobin, serum calcium, and albumin concentrations, and usage of renin-angiotensin system blockers and beta blockers.

*Left ventricular end-diastolic dimension was adjusted for sex, body mass index, underlying diabetes and cardiac disease, smoking status, hemoglobin, serum phosphorus and albumin levels, log transformed high-sensitivity C-reactive protein, and usage of renin-angiotensin system blockers and beta blockers.

*Left ventricular end-systolic dimension was adjusted for sex, diastolic blood pressure, underlying cardiovascular disease, smoking status, hemoglobin, serum phosphorus, albumin, and creatinine concentrations, log transformed high-sensitivity C-reactive protein, and usage of renin-angiotensin system blockers and beta blockers.

*Left atrial dimension was adjusted for age, sex, pulse pressure, underlying diabetes and cardiac disease, smoking status, hemoglobin, serum albumin levels, log transformed high-sensitivity C-reactive protein, and usage of diuretics, beta blockers, calcium channel blockers, and aspirin.

Abbreviations: TSAT, transferrin saturation; OR, odds ratio; CI, confidence interval.
doi:10.1371/journal.pone.0087231.t005
stepwise increase in all-cause mortality, with the first significant increase in patients with TSAT \( \leq 20\% \). Based on these findings, we tried to elucidate the impact of iron deficiency as a proxy of iron overload, and thus categorized patients into just 'low' and 'normal to high' TSAT groups. Moreover, TSAT was found to be a significant determinant of LVMI and Ln hs-CRP concentrations in multivariate linear regression analysis. Taken together, the impact of 'low' TSAT on clinical outcome in our patients seems to be partly mediated by LVH and inflammation.

Several shortcomings of the current study should be discussed. First, since the study subjects were all Korean incident ESRD patients, the association of TSAT with mortality and composite outcome may not be generalizable to other populations. Second, because only the baseline laboratory and echocardiographic measurements were used for the analysis, it was difficult to demonstrate the impact of the changes of TSAT on patients' clinical outcomes. Third, even though CV disease was the leading cause of death in our subjects, CV mortality was comparable among the three groups in spite of a significant difference in all-cause mortality, which may be attributed to 'low' CV mortality rates in the current study compared to those in previous studies on Western ESRD patients. We propose that the difference is mainly attributed to disparate ethnicities as the mortality rates of our patients were not significantly different from those of Japanese dialysis patients [47]. Fourth, we stratified the patients based on TSAT only, without considering ferritin levels, indicating that patients with TSAT \( \leq 20\% \) may not be purely iron deficient. Since ferritin is an acute-phase reactant, high ferritin concentrations with low TSAT may imply a condition of iron sequestration, which is a characteristic of 'anemia of chronic disease'. In the present study, in fact, there was a significant correlation between serum ferritin concentrations and ln TSAT (r = 0.368, P < 0.001), whereas Hb levels did not correlate with serum ferritin concentrations (r = 0.002, P = 0.954). Fifth, TSAT is also known to be influenced by nutritional status. TIBC may be decreased due to reduced transferrin synthesis in the setting of malnutrition and chronic disease, resulting in high TSAT, disproportionate to the iron content [11]. However, serum albumin levels were not significant.

**Table 6. Odds ratios and 95% confidence intervals for serum inflammatory and cardiac biomarkers according to baseline TSAT concentrations (Logistic regression analysis).**

|                | Unadjusted | Adjusted |
|----------------|------------|----------|
|                | OR  | 95% CI   | P    | OR  | 95% CI   | P    |
| hs-CRP \( \geq 3 \) mg/dL |    |          |      |    |          |      |
| TSAT \( \leq 20\% \) or \( > 40\% \) | 1.772 | 1.162–2.702 | 0.008 | 2.087 | 1.292–3.372 | 0.003 |
| 20% < TSAT \( \leq 40\% \) | 1   |          |      | 1   |          |      |
| TSAT >40%      | 0.980 | 0.558–1.722 | 0.945 | 0.817 | 0.443–1.506 | 0.517 |
| NT-proBNP \( \geq 10000 \) pg/mL |    |          |      |    |          |      |
| TSAT \( \leq 20\% \) or \( > 40\% \) | 1.630 | 1.124–2.363 | 0.010 | 2.039 | 1.181–3.521 | 0.011 |
| 20% < TSAT \( \leq 40\% \) | 1   |          |      | 1   |          |      |
| TSAT >40%      | 0.640 | 0.400–1.023 | 0.062 | 0.328 | 0.171–0.629 | 0.001 |
| Troponin-T \( \geq 0.1 \) ng/mL |    |          |      |    |          |      |
| TSAT \( \leq 20\% \) or \( > 40\% \) | 1.498 | 1.004–2.235 | 0.048 | 2.019 | 1.104–3.691 | 0.023 |
| 20% < TSAT \( \leq 40\% \) | 1   |          |      | 1   |          |      |
| TSAT >40%      | 0.876 | 0.518–1.484 | 0.623 | 0.989 | 0.484–2.024 | 0.976 |

*hs-CRP was adjusted for Charlson Comorbidity Index, subjective global assessment score, smoking status, hemoglobin, serum calcium, glucose, albumin, and sodium concentrations, and log transformed ferritin.

*NT-proBNP was adjusted for diastolic blood pressure, underlying diabetes and cardiac disease, hemoglobin, serum glucose, albumin, creatinine, and sodium levels, log transformed high-sensitivity C-reactive protein, log transformed ferritin, log transformed troponin-T, and usage of renin-angiotensin system blockers, diuretics, and beta blockers.

*Troponin-T was adjusted for sex, systolic blood pressure, underlying diabetes and cardiac disease, subjective global assessment score, hemoglobin, serum calcium, glucose, albumin concentrations, log transformed high-sensitivity C-reactive protein, log transformed ferritin, log transformed 24-hr urine volume, left atrial dimension, left ventricular mass index, left ventricular ejection fraction, and usage of diuretics and nitrate.

Abbreviations: hs-CRP, high-sensitivity C-reactive protein; NT-proBNP, N-terminal pro B-type natriuretic peptide; TSAT, transferrin saturation; OR, odds ratio; CI, confidence interval.

doi:10.1371/journal.pone.0087231.t006
cantly different among the three groups, suggesting that TSAT was not largely affected by nutritional status in our patients. Sixth, data for transfusion were not available. So, we excluded patients who had a history of acute/recent bleeding in the analysis. Lastly, about one-third of patients were already taking iron or ESA agents at the time of inclusion. Nevertheless, the proportions of patients taking those medications were not significantly different among the three groups, and multivariate analysis was conducted after adjusting for these factors. Despite these limitations, to our knowledge, the current study is the first study to investigate the impact of TSAT at the time of dialysis initiation on clinical outcome in a large and single-ethnicity incident dialysis patient cohort. Further studies will be needed to elucidate whether serial monitoring, rather than a single measurement of TSAT, is helpful in identifying ESRD patients at a high risk of all-cause and CV morbidity and mortality and whether iron supplements are beneficial to clinical outcome in ‘low’ TSAT patients.

In conclusion, ‘low’ TSAT was a significant independent risk factor for CV composite outcome and all-cause mortality in incident dialysis patients with anemia. Furthermore, TSAT ≤20% was significantly associated with LVMI and hs-CRP concentrations. These findings suggest that the adverse clinical outcomes in patients with ‘low’ TSAT are partly attributed to LVH and inflammation.

Supporting Information
Figure S1 Kaplan-Meier curves for CV composite outcome (A) and all-cause mortality (B) according to baseline TSAT concentrations. The CV composites and all-cause mortality rates were significantly higher in patients with TSAT ≤20% compared to patients with TSAT >20%. Abbreviation: CV, cardiovascular; TSAT, transferrin saturation.

Table S1 Comparisons of clinical outcomes between patients with TSAT ≤20% and TSAT >20%.

Table S2 Hazard ratios and 95% confidence intervals for primary and secondary endpoints according to baseline TSAT concentrations (Cox-proportional hazard regression analysis).

Table S3 Multivariate linear regression analysis for left ventricular mass index.

Table S4 Multivariate linear regression analyses for inflammatory and cardiac biomarkers.

Author Contributions
Conceived and designed the experiments: HMK SWK. Performed the experiments: HMK EJK JHH JSH. Analyzed the data: HMK CHK FMD MJL. Contributed reagents/materials/analysis tools: HMK HJO JTP SHH THY. Wrote the paper: HMK SWK.

References
1. Robinson BE (2006) Epidemiology of chronic kidney disease and anemia. J Am Med Dir Assoc 7: S3–6; quiz S17–21.
2. McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, et al. (2004) The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 20: 1501–1510.
3. Vlagopoulos PT, Tighiouart H, Weiner DE, Griffith J, Pettitt D, et al. (2005) Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol 16: 3493–3410.
4. Portoles J, Lopez-Gomez JM, Aljama P (2007) A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: the MAR Study. Nephrol Dial Transplant 22: 500–507.
5. Tang YD, Katz SD (2006) Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 113: 2454–2461.
6. Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, et al. (2003) The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 63: 1499–1507.
7. Koedves CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE (2006) Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 69: 560–564.
8. Weiss G, Goodman LT (2003) Anemia of chronic disease. N Engl J Med 352: 1011–1023.
9. (2006) KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47: 511–415.
10. (2012) KDOQI Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney international supplements 2: 292–335.
11. Wish JB (2006) Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 1 Suppl 1: S4–8.
12. Wang J, Pantopoulos K (2011) Regulation of cellular iron metabolism. Biochem J 434: 365–381.
13. Dong F, Zhang X, Culver B, Chew HG Jr., Kelley RO, et al. (2005) Dietary iron deficiency induces ventricular dilatation, mitochondrial ultrastructural aberrations and cytochrome c release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci (Lond) 109: 277–286.
14. Naito Y, Tsujino T, Matsumoto M, Sakota T, Ohyanagi M, et al. (2009) Adaptive response of the heart to long-term anemia induced by iron deficiency. Am J Physiol Heart Circ Physiol 296: H583–593.
15. van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC (2011) Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol 8: 403–409.
16. Okenko DO, Maudel AK, Missouri CG, Poole-Wilson PA (2011) Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol 58: 1241–1251.
17. Jankowska EA, von Haeffling S, Anker SD, Macdougall IC, Ponikowski P (2013) Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 34: 816–829.
18. Beutler E, Waalen J (2006) The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 107: 1747–1750.
19. Michels WM, Groentendorst DC, Vredenburgh M, Elliott EG, Dekker FW, et al. (2010) Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol 5: 1001–1009.
20. Steiber AL, Kalantar-Zadeh K, Secker D, McCarthy M, Sehgal A, et al. (2004) Subjective Global Assessment in chronic kidney disease: a review. J Ren Nutr 14: 191–200.
21. Park HJ, Kim S, Yong JS, Han SS, Yang DH, et al. (2007) Reliability and validity of the Korean version of Kidney Disease Quality of Life instrument (KDQOL-SF). Tohoku J Exp Med 211: 321–329.
22. Derveer RB, Alonso DR, Lutas EM, Gottlieb GI, Campo E, et al. (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57: 450–458.
23. Liao Y, Cooper RS, Durazo-Arvizu R, Mensah GA, Ghali JK (1997) Prediction of mortality risk by different methods of indexation for left ventricular mass. J Am Coll Cardiol 29: 641–647.
24. Li S, Collins AJ (2004) Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int 65: 626–633.
25. Druke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, et al. (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 353: 2071–2081.
26. Singh AK, Szczec L, Tang KL, Bahnart H, Sapp S, et al. (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2055–2061.
27. Pfeffer MA, Buurmann EA, Chen CY, Cooper ME, de Zeeuw D, et al. (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019–2032.
28. Anand IS (2008) Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol 52: 501–511.
30. Nanas JN, Matsouka C, Karageorgopoulos D, Leoniti A, Tselakis E, et al. (2006) Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 48: 2485–2489.
31. Toblli JE, Lombrana A, Duarte P, Di Gennaro F (2007) Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50: 1657–1665.
32. Silverberg DS, Wedler D, Iaina A, Schwartz D (2008) The role of correction of anemia in patients with congestive heart failure: a short review. Eur J Heart Fail 10: 819–823.
33. Franchini M, Targher G, Montagnana M, Lippi G (2008) Iron and thrombosis. Ann Hematol 87: 167–173.
34. Dallman PR (1986) Biochemical basis for the manifestations of iron deficiency. Annu Rev Nutr 6: 13–40.
35. Maeder MT, Khammy O, dos Remedios C, Kaye DM (2011) Myocardial and systemic iron depletion in heart failure implications for anemia accompanying heart failure. J Am Coll Cardiol 58: 474–480.
36. Anker SD, Comin-Colet J, Filippatos G, Willenheimer R, Dickstein K, et al. (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361: 2436–2446.
37. Comin-Colet J, Lainscak M, Dickstein K, Filippatos GS, Johnson P, et al. (2013) The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. Eur Heart J 34: 30–38.
38. Murphy CJ, Oudit GY (2010) Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. J Card Fail 16: 888–900.
39. Kremastinos DT, Farmakis D (2011) Iron overload cardiomyopathy in clinical practice. Circulation 124: 2253–2263.
40. Mainous AG 3rd, Gill JM, Carek PJ (2004) Elevated serum transferrin saturation and mortality. Ann Fam Med 2: 133–138.
41. Ellervik C, Tybjærg-Hansen A, Nordestgaard BG (2011) Total mortality by transferrin saturation levels: two general population studies and a metaanalysis. Clin Chem 57: 459–466.
42. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, et al. (2004) Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int 65: 1492–1498.
43. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, et al. (2001) Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 12: 2759–2767.
44. Cachofeiro V, Goicochea M, de Vinuesa SG, Oubina P, Lahera V, et al. (2008) Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl S4–9.
45. Danesh J, Wheeler JG, Hirschfield GM, Esa S, Eiriksdottir G, et al. (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350: 1387–1397.
46. Han SS, Ahn JM, Chin HJ, Chae DW, Oh KH, et al. (2010) Impact of C-reactive protein and pulse pressure evaluated at the start of peritoneal dialysis on cardiovascular events in the course of treatment with peritoneal dialysis. Perit Dial Int 30: 300–310.
47. Robinson BM, Port FK (2009) International hemodialysis patient outcomes comparisons revisited: the role of practice patterns and other factors. Clin J Am Soc Nephrol 4 Suppl 1: S12–17.